Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
J Pediatr Gastroenterol Nutr ; 49(3): 335-42, 2009 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-19543116

RESUMO

OBJECTIVES: To evaluate growth in Italian patients with cystic fibrosis (CF). PATIENTS AND METHODS: A multicentre cross-sectional study was carried out on patients with CF attending Italian reference centres. Anthropometric data were evaluated using the Centers for Disease Control and Prevention 2000 reference data. Nutritional failure was defined as height-for-age percentile (HAP) <5th (all patients); weight-for-length percentile (WLP) <10th (patients <2 years); body mass index percentile (BMIp) <15th (patients between 2 and 18 years). The risk of malnutrition (defined as HAP, WLP, and BMIp <25th) and the proportion of patients below the "BMIp goal" (BMIp > or =50th) were also evaluated. Nutritional status was evaluated in the whole population and in relation to age, sex, pancreatic insufficiency, meconium ileus, and lung function. RESULTS: A total of 892 patients with CF (50.7% males, mean age 9.2 years, range 0.1-18 years) were enrolled. The proportion of children with HAP <5th, WLP<10th and BMIp<15th was 12.2%. 12.9%, 20.9%, respectively, and 54.4% did not fulfill the BMIp > or =50th goal. HAP <25th identified the highest proportion of children at risk of malnutrition, whereas BMIp <15th identified the highest proportion of children with nutritional failure. Whatever the criterion used to define malnutrition, the highest proportion of children with nutritional failure was found in adolescence (11-18 years). z scores for height, weight, and BMI were significantly associated with pancreatic status and lung function. Differences among centres for the auxologic parameters were not significant, except for BMIp. CONCLUSIONS: Nutritional failure is present in a minority of Italian patients with CF, particularly during adolescence. Different auxologic indicators should be used for identifying children at risk for or with actual malnutrition.


Assuntos
Tamanho Corporal , Fibrose Cística/complicações , Transtornos do Crescimento/etiologia , Desnutrição/etiologia , Adolescente , Fatores Etários , Índice de Massa Corporal , Criança , Pré-Escolar , Estudos Transversais , Fibrose Cística/fisiopatologia , Transtornos do Crescimento/epidemiologia , Humanos , Lactente , Itália , Pulmão/fisiopatologia , Masculino , Desnutrição/diagnóstico , Desnutrição/epidemiologia , Pâncreas/fisiopatologia , Prevalência , Risco
2.
Ital J Pediatr ; 37: 22, 2011 May 17.
Artigo em Inglês | MEDLINE | ID: mdl-21586141

RESUMO

Cystic Fibrosis (CF) is the most frequent recessive disease of Caucasian patients. Association with other diseases or syndromes has previously been reported. Co-morbidity may be a challenge for clinicians, who have to face more severe problems. We have described a CF infant, F508del homozygote, diagnosed by neonatal screening, who also had a chromosome 18q terminal deletion [del (18)(q22-qter)]. Some clinical features of the 18q deletion: e.g., cardiopathy, gastro-oesophageal reflux and severe muscular hypotonia, worsened the CF clinical picture and his quality of life, with repeated pulmonary exacerbations and failure to thrive in the first six months of life. The treatment strategy was chosen following an accurate multi-disciplinary team study of overlapping chromosome syndrome and CF symptoms. The use of a gastrostomy device for enteral nutrition together with a new device (Ez-PAP) for chest physiotherapy led to normal growth, a notably reduced hospitalization rate and improved quality of life. This case shows how co-morbidities worsening the clinical course of a "complicated patient" can be faced thanks to unconventional therapies that represent a challenge for clinicians.


Assuntos
Deleção Cromossômica , Cromossomos Humanos Par 18/genética , Fibrose Cística/genética , Furosemida/uso terapêutico , Oxigenoterapia/métodos , Extratos Pancreáticos/administração & dosagem , Pré-Escolar , Fibrose Cística/epidemiologia , Fibrose Cística/terapia , Diuréticos/uso terapêutico , Seguimentos , Humanos , Masculino , Morbidade/tendências
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA